Abstract
Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.
MeSH terms
-
Arthritis, Psoriatic / drug therapy*
-
Arthritis, Psoriatic / immunology
-
Etanercept
-
Humans
-
Immunoglobulin G / adverse effects
-
Immunoglobulin G / pharmacology*
-
Immunoglobulin G / therapeutic use
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / pharmacology*
-
Immunosuppressive Agents / therapeutic use
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Tumor Necrosis Factor-alpha / drug effects*
-
Tumor Necrosis Factor-alpha / metabolism
Substances
-
Immunoglobulin G
-
Immunosuppressive Agents
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Etanercept